Skip to content

NALDEBAIN for Postoperative Pain Management in Take Down of Anastomosis

NALDEBAIN for Postoperative Pain Management in Take Down of Anastomosis

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03854851
Enrollment
40
Registered
2019-02-26
Start date
2019-03-01
Completion date
2019-10-31
Last updated
2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Naldebain, long-term analgesia, take down of anastomosis

Brief summary

NALDEBAIN ER injection, invented by Taiwanese, launched in 2017, is a nalbuphine synthetic prodrug with oil-based solution to extend the release in human body by intramuscular injection. It was approved for the premedication use for moderate to severe pain relief, expected after surgery. There was limited experience with the combination of medication and different type of surgeries. Only the effect of operative analgesia on the hemorrhoidectomy patients have been well studied. Through reviewing the past medical cases, the pain intensity after receiving take down of anastomosis was about 4 to 7 points (moderate pain), lasing about 1 to 3 days. It was a suitable population with multi-day analgesic unmet need. At present, the standard treatment after take down of anastomosis in the CMUH was morphine as needed. This treatment might not provide for well-controlled postoperative pain management. Patients might receive more painkillers when they needed than before pain occurred. Plus, it also cost more postoperative medical care. Therefore, this study intended to compare the standard treatment and NALDEBAIN for postoperative outcomes, safety and satisfaction. The study will enroll patients scheduled to electively undergo take down of anastomosis. Eligible subjects were randomly divided into two groups, one receiving NALDEBAIN and the other receiving standard treatment. The study will evaluate pain intensity, dosage of supplement analgesics, incidence of adverse reactions, patient satisfaction, time of the first fart after surgery, and duration of postoperative hospital stay.

Detailed description

This is an open-labeled, randomized clinical trial. After ICFs are signed, patients' medical history will be gained for checking if they are eligible for this study or not. And then, on Day -1, eligible ones will randomly be divide into two separate group: NALDEBAIN or MORPHINE. Group NALDEBAIN will receive Nadebain by gluteus maximus injection between 12 and 24 hours prior to surgery for postoperative pain relief. Group MORPHINE will receive morphine as needed after surgery. All necessary data will be gain form EMR or patient dairies.

Interventions

In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.

In Morphine group, patients will receive morphine as needed after surgery.

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Men and Women between 20 and 80 years of age 2. History of laparoscopic surgery 3. American Society of Anesthesiology Physical Class 1-3 4. Ability and willingness to provide informed consent

Exclusion criteria

1. History of hypersensitivity or allergy to opioid, NSAIDs, or Acetaminophen 2. Chronic preoperative opioid use 3. Severe comorbidity which is able to interfere pain assessment 4. Ostomy surgery of intestine within the past 8 weeks 5. Pregnant or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Supplemental analgesicsFrom Day 0 to Day 7The consumption of total amount (mg) of supplemental analgesics administered after surgery.

Secondary

MeasureTime frameDescription
Pain assessment: VAS2 hours after surgeryUsing visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain)
Pain assessment: area under the curve of VASFrom post-OP to Day 7Pain assessment (time-specific pain intensity) calculated as the area under the curve of VAS pain intensity scores through 7 days after surgery
Patient satisfaction: frequency of each optionDay 7Calculating the frequency of each option: highly satisfied, satisfied, uncertain, dissatisfied and very dissatisfied
frequency of adverse eventFrom Day-1 to Day 7Recording the frequency of treatment-emergent adverse event (TEAE)

Other

MeasureTime frameDescription
Time of first fartingFrom post-OP to Day 7Observing when patients are able to pass gas after surgery
Date of dischargeFrom post-OP to Day 7Observing when the condition of patients is good enough to discharge

Countries

Taiwan

Contacts

Primary ContactHung-Chang Chen
D96591@mail.cmuh.org.tw04-22052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026